BDNF and Alzheimer disease: Future studies are warranted to confirm our findings on changes in plasma NDEV biomarkers in advanced AD and after treatment with Cerebrolysin® and donepezil, as well as on correlations of these biomarkers with the neurotrophic and inflammatory factors BDNF and TNF-α, because this is the first report on these topics.